data + articles · 2 listed
newest 2001spec sheet6 rows
PEPA came out of Japan's National Institute of Neuroscience in the mid-1990s as a sulfonamide-based AMPA receptor potentiator, and researchers there quickly realized it was up to 100 times more potent in vitro than the racetam aniracetam at the same job. Rather than becoming a drug candidate, it became a reference tool; its unusual preference for GluA3 and GluA4 subunits let scientists map receptor subtype pharmacology in ways cruder compounds couldn't. It did show real translational promise, improving memory in rats after ischemic brain injury when given systemically, but no pharmaceutical company appears to have picked it up for clinical development. It remains, decades later, mostly a lab reagent rather than a museum piece with a failed-trial story; a compound whose whole career happened on the bench.
- Up to 100x more potent than aniracetam as an AMPA potentiator in vitro
- Improved memory performance in rats after ischemic brain injury
- Useful tool for distinguishing AMPA receptor subunit pharmacology
- Well characterized mechanism among AMPA PAMs
- PEPA is roughly 100 times more potent than the racetam aniracetam at potentiating AMPA receptors in vitro.
- Despite promising post-ischemic memory data in rats, no company appears to have ever taken PEPA into human development.
Mechanism
Binds an extracellular site and attenuates desensitization, with selective preference for GluA3 and GluA4 flip/flop subunit combinations over GluA1/GluA2.
Safetyrisks and cautions, not medical advice
PEPA is a research-grade allosteric AMPA-receptor potentiator studied only in animals, so no human safety profile, tolerability data or contraindications exist. The central class concern is that AMPA potentiation is intrinsically excitatory: high-impact ampakines have produced calcium-dependent neuronal toxicity and convulsions in vivo, and PEPA is a relatively strong potentiator rather than a low-impact one, which places the theoretical seizure and excitotoxicity risk toward the higher end of the class. Preclinical dosing has been intravenous at defined milligram-per-kilogram levels, with no established safe human exposure. Beyond the mechanism-based risk, it is an unregulated compound of unverified purity when obtained grey-market. It should be regarded as experimental, with a plausible convulsant liability that has not been ruled out in people.
History
First described by Sekiguchi et al. in 1997 (Journal of Neuroscience); further receptor-subtype characterization followed in 1998; post-ischemic memory rescue reported around 2001. Never advanced beyond academic and pharma-tool use.
Subjective profileweighing the evidence above
One of the most mechanistically interesting AMPA PAMs on record, and also one that never left the lab bench for a clinical trial.
Resources
This entry is here for reference.
Research
- 1.A novel allosteric potentiator of AMPA receptors: 4-[2-(phenylsulfonylamino)ethylthio]-2,6-difluoro-phenoxyacetamide
- 2.The AMPA receptor allosteric potentiator PEPA ameliorates post-ischemic memory impairment
2 listed here; entry last updated July 2026
Reviews
My notesprivate to this device
FAQ
Is PEPA available as a supplement?
No. PEPA is a research chemical used in laboratory pharmacology studies; it was never developed, tested, or sold as a human supplement or drug.
What makes PEPA different from other AMPA potentiators?
It shows a strong preference for the GluA3 and GluA4 receptor subunits over GluA1/GluA2, which made it a useful tool for scientists mapping which AMPA subtypes drive which effects.
Limitations of the evidence
- No human data exists; safety profile is unknown outside animal studies
Notes and cautions
- Never formulated or dosed as a drug candidate